Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed
at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in
patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.